Amgen Phase III Data Could Add Second Indication To Uplizna’s Label

 
• By Joseph Haas
  
Rare disease
Amgen's hopes Uplizna can become the first approved therapy for IgG4-RD • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D